Tag Archives: USPTO

Kyle Bass Files Second IPR Petition

Attribution: Vlad Lazarenko via Wikimedia Commons

Today hedge fund manager Kyle Bass has continued his reported “short activist strategy” campaign by filing a second Inter Partes Review (IPR) petition with the U.S. Patent and Trademark Office (USPTO). BIO expressed grave concerns with this exploitation of the patent challenge system following Mr. Bass’ initial filing earlier this month. Follow the below links to read more. BIO’s prior statement issued following Kyle Bass’ first IPR Petition When The Deck is Stacked Against Innovators, Everyone Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

When The Deck is Stacked Against Innovators, Everyone Loses

US_Patent_And_Trademark_Office

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the USPTO’s Inter Partes Review system (IPR). Joined by several of BIO’s member companies, we expressed our concerns with how the system is evolving into one which makes it easier for IPR challengers to win than in Federal Court. The implementation of the IPR system – developed through the 2011 America Invests Act – has unintentionally invited abuses of the USPTO Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Deputy General Counsel Remarks on Revised Eligibility Guidance

Supreme Court

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property recently spoke at the U.S. Patent and Trademark Office’s public forum on patent-eligible subject matter. The forum was a chance for the Office to receive public feedback regarding the most recently revised Eligibility Guidance for determining subject matter under 35 U.S.C. 1010. Biotechnology advocates are concerned that PTO examiners have interpreted recent decisions by the U.S. Supreme Court, including those in Alice Corp, Myriad, and Mayo Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

USPTO Issues New Myriad Guidance

Kaylee_dna_115x76

On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2014

shutterstock_26191726

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,